Dialysis + Transplant Flashcards

1
Q

Haemodialysis Principles

A

Blood + dialysate flow in opposite directions –> countercurrant mechanisms maintain conc. gradient throughout exchange surface
For diffusion losses to occur–> small amounts K+ and other solutes in dialysate, so K+ diffuses out of blood
For additions to occur–> large vol of bicarbonate in dialysate, flows into blood
For water loss–> increase pressure of blood + decrease pressure of dialysate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Haemodialysis Circulatory access- temporary

A

Central venous catheter (enters internal jugular + sits in right atrium)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Haemodialysis Circulatory access- permanent

A

Arterio-venous fistula (artery + vein joined together to arterialise vein) where blood can be removed + added back in

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Haemodialysis- GFR

A

When patient on machine, clearance is excellent, but rest of time have no kidney function
Averages out to GFR 10-12ml/min

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Haemodialysis Advantages

A

Better clearance
Short time for treatment
Not dependent on patient competence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Haemodialysis Disadvantages

A
Hospital
Limited by staff and spaces
Requires circulatory access- complications including thrombosis + infection (LMWH + antibiotics)
Cardiovascularly demanding
Restricted diet
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Peritoneal dialysis Principle

A

Catheter placed in patient’s abdomen –> travels under skin + enters peritoneal cavity at midline
Uses peritoneum as semi-permeable membrane
Capillaries run outside the peritoneal membrane carrying solutes etc.
Dialysate pumped into peritoneal cavity + exchange processes occur across the peritoneal membrane
Dialysate contains low conc. of waste product (to encourage to diffuse out of blood) and high conc. glucose + larger molecules (to promote diffusing into blood)
Can also deliver things to patient such as bicarb/lactate for buffering + amino acids for nutrition
Closed space –> conc. gradients equal out –> have to drain fluid + replace

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Peritoneal dialysis GFR

A

Slightly less efficient than haemodialysis
GFR around 7-8ml/min
Some renal function must remain
Can be done almost continuously unlike haemodialysis
4 x 2L exchanges per day- 30 mins per exchange

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Peritoneal Dialysis advantages

A

Easy access
Haemodynamically stable
Increased patient mobility –> do not have to remain close to hospital
Home based –> maintains patient independence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Peritoneal Dialysis disadvantages

A
Lower rate of clearance
Infection (peritonitis) and adhesions can occur
Membrane failure
Intra-abdominal catheter required
Dependent on patient competence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Renal transplant prognosis

A

Lower risk of death compared to both types of dialysis
Initial risk of death is higher in those receiving a transplant due to surgical complications, immunosuppression and recovery period
Takes about half a year for RR of death to become lower than patients remaining on transplant risk, but after this time risk is continuously getting lower

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Renal transplant advantages

A
Increased survival
Continuous therapy (dialysis) not needed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Renal transplant disadvantages

A

Risk of rejection
Lifelong immunosuppression
Have to find suitable donor
Psychological problems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Blood group

A

People can’t receive transplant to which they have pre-formed antibodies against
All blood groups can donate to themselves
O can donate to anybody but only receive from O
A and B can donate to AB
A and B cannot donate to each other

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

HLA Class I

A

Present in all cells

A,B,C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

HLA Class II

A

Present in APCs

DR, DQ, DP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

HLA genetics

A

Found on chromosome 6
Inherited via simple Mendelian inheritance
Everyone has 2 alleles for each HLA subtype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

HLA compatibility

A

0MM= all same types
6MM= none of same types
HLA DR, B and A most important

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Antibodies

A

Sensitising events- pregnancy, previous transplant, blood transfusion
Detected via direct cross match- Patients serum mixed with donor tissue- if reaction occurs, transplant contraindicated

20
Q

Non-immunological matching

A

Age
Comorbidity
Gender
Cold ischaemia time (longer= poorer function)
Donor type (DBD better outcome than DCD as circulation intact for longer)

21
Q

MHC

A

Presents fragments of non-self proteins to T cells in order to initiate an immune response

22
Q

HLA Class I immune response

A

HLA A,B,C subtypes
Present on all nucleated cells
Present endogenous antigens to CD8 T cells
Self antigens do not stimulate response due to immunological tolerance

23
Q

HLA Class II immune response

A

HLA DR, DQ, DP subtypes
Present on antigen presenting cells
Present exogenous peptides to CD4 T cells

24
Q

HLA recognition- Direct pathway

A

Donor APCs present foreign particles to recipient CD8 T cells leading to their activation
Response for acute, cell mediated rejection

25
Q

HLA rejection- Indirect pathway

A

Donor cells/proteins are shed from graft + are engulfed and presented by recipient APCs to CD4 T cells
Mediated more chronic graft rejection

26
Q

T cells

A

Th1- activate macrophages + synthesis of important inflammatory cytokines
Th2- help with B cell responses

27
Q

B cells

A

Responsible for antibody production
CD4 T cells can activate B cells + cause differentiation into plasma cells that churn out large quantities of antibodies
Antibodies can play a role in graft rejection via activation of complement + cell mediated damage

28
Q

Calcineurin inhibitors examples

A

Tacrolimus

Cyclosporine

29
Q

Tacrolimus, Cyclosporine

A

Calcineurin inhibitors

30
Q

Calcineurin inhibitors MOA

A

Prevent action of calcineurin on stimulating transcription of T cell activating genes (including IL2) to prevent T cell clonal expansion

31
Q

Calcineurin inhibitors SE

A
Nephrotoxicity
Headaches
New onset diabetes after transplant
hypertension
Liver dysfunction
Increases risk of post-transplant malignancy
32
Q

Azathioprine

A

Anti-metabolite agent
Purine analogue that selectively inhibits purine synthesis which inhibits cell proliferation
SE= Myelosuppression, hepatitis, cholestasis

33
Q

Mycophenolate

A
Antimetabolite
Inhibits enzymes (IMPDH) involved in purine synthesis to prevent cell proliferation
SE= GI, myelosuppression, infections (CMV)
34
Q

mTOR inhibitors examples

A

Everolimus

Sirolimus (rapamycin)

35
Q

Everolimus, sirolimus

A

mTOR inhibitors

36
Q

mTOR inhibitors MOA

A

Inhibits IL2 + other cytokines signal transduction via action on mTOR
Decreases T and B cell activation

37
Q

mTOR inhibitors SE

A

Impaired wound healing
Lymphocele formation
Pneumonitis
Mouth ulcers

38
Q

Corticosteroids

A

Decrease cytokine gene transcription to decrease cytokine regulated lymphocyte signalling which decreases proliferation

39
Q

Corticosteroid SE

A
Insomnia
Wright gain
Hypertension
CV risk increased
Impaired glucose tolerance
Poor wound healing
Osteoporosis
40
Q

IL 2 monoclonal antibodies

A

Basiliximab
Prevents IL2 induced T cell proliferation + clonal expansion
SE= few

41
Q

Co-stimulation inhibitors

A

Belatacept
Fusion protein of Fc portion of IgG and CTLA-4
Inhibit T cell signalling

42
Q

Anti-rejection therapy- Infection

A

Bacterial- UTI, pneumonia, TB
Fungal
Viral:
-CMV (4 weeks–> 6months after transplant–> mono, retinitis, colitis)
-EBV= >6months after transplant –> mono like illness, PTLD
- BK –> BK virus nephritis

43
Q

Anti-rejection therapy- cancer

A

Skin–> mostly non melanoma skin cancer
Lymphoma
Kaposi sarcoma (caused by HHV8)

44
Q

Anti-rejection conditions- metabolic

A

Diabetes mellitus
Hypertension
Osteoporosis

45
Q

Heart beating donations

A

Live donors

Donation after brain death (DBD)

46
Q

Donation after brain death criteria

A

Absence of 6 reflexes (pupillary, corneal, vestibule-ocular, gag, cough, pain)
Confirmed apnoea
At least 2 doctors registered with GMC >5 years and at least 1 is consultant
Tests performed twice
Heart+ lungs still working while on life supported
Organs transplanted are in better conditions

47
Q

Non heart beating donations

A

Donation after cardiac death (DCD)- organs in worse condition
Controlled- donor taken to theatre before life support turned off
Uncontrolled- donor taken to theatre after